18F-FDG PET in the diagnosis and follow-up of thyroid malignancy

In Vivo

Volumn 22, Issue 1, 2008, Pages 109-114

  Al Nahhas, A ^a   Khan, S ^a   Gogbashian, A ^a   Banti, E ^b   Rampin, L ^b   Rubello, Domenico ^b,c  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b Rovigo Hospital   (Italy)

^c VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

18F FDG PET; Differential diagnosis; Follow up; Review; Serum thyroglobulin levels; Thyroid incidentaloma; Well differentiated thyroid carcinoma

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 123; IODINE 131; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; RECOMBINANT THYROTROPIN; TECHNETIUM 99M; THYROGLOBULIN; THYROTROPIN; DIAGNOSTIC AGENT; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT;

ASPIRATION BIOPSY; BENIGN TUMOR; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DRUG UPTAKE; FOLLOW UP; HUMAN; INCIDENTAL FINDING; MALIGNANT NEOPLASTIC DISEASE; MEDLINE; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; QUANTITATIVE ANALYSIS; REVIEW; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; THYROID CARCINOMA; THYROID INCIDENTALOMA; THYROID NODULE; THYROID TUMOR; BLOOD; METABOLISM; METHODOLOGY; PATHOLOGY; SCINTISCANNING;

DIAGNOSIS, DIFFERENTIAL; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; THYROGLOBULIN; THYROID NEOPLASMS; THYROID NODULE;

EID: 40749083948     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Coleman P, Babb P and Damiecki P: Cancer survival trends in England and Wales 1975-1995: deprivation and NHS region. London: Stationery Office, pp. 471-478, 1999.
2. Hundahl SA, Fleming ID, Fremgen AM and Menck HR: Anatomical cancer data base report on 53, 856 cases of thyroid carcinoma treated in the U.S. in 1985-1995. Cancer 83: 2638-2648, 1998.
3. Mortensen JD, Woolner LB and Bennett WA: Gross and microscopic findings in clinically normal thyroid glands. J Clin Endocrinol Metab 15: 1270-1280, 1995.
4. Burguera B and Gharib H: Thyroid incidentalomas. Prevalence, diagnosis, significance, and management. Endocrinol Metab Clin North Am 29: 187-203, 2000.
5. Castro MR and Gharib H: Thyroid fine-needle aspiration biopsy: progress, practice, and pitfalls. Endocr Pract 9: 128-136, 2003.
6. Warburg O: On the origin of cancer cells. Science 123: 309-314, 1956.
7. Hustinx R, Benard F and Alavi A: Whole-body FDG-PET in the management of patients with cancer. Semin Nucl Med 32: 35-46, 2002.
8. 18FDG PET and PET/CT oncologic imaging. Semin Nucl Med 34: 122-133, 2004.
9. Schoder H and Yeung HW: Positron emission imaging of head and neck cancer, including thyroid carcinoma. Semin Nucl Med 34: 180-197, 2004.
10. Yasuda S, Shohtsu A, Ide M, Takagi S, Takahashi W, Suzuki Y and Horiuchi M: Chronic thyroiditis: diffuse uptake of FDG at PET. Radiology 207: 775-778, 1998.
11. Boerner AR, Voth E, Theissen P, Wienhard K, Wagner R and Schicha H: Glucose metabolism of the thyroid in Graves' disease measured by F-18-fluoro-deoxyglucose positron emission tomography. Thyroid 8: 765-772, 1998.
12. 18F-FDG uptake in thyroid nodules found incidentally on whole-body PET-CT. Nucl Med Commun 28: 373-381, 2007.
13. Are C, Hsu JF, Schoder H, Shah JP, Larson SM and Shaha AR: FDG-PET detected thyroid incidentalomas: need for further investigation? Ann Surg Oncol 14: 239-247, 2007.
14. Cohen MS, Arslan N, Dehdashti F, Doherty GM, Lairmore TC, Brunt LM and Moley JF: Risk of malignancy in thyroid incidentalomas identified by fluorodeoxyglucose-positron emission tomography. Surgery 130: 941-946, 2001.
15. 18F-fluorodeoxyglucose positron emission tomography for metastasis evaluation and cancer screening in healthy subjects. J Clin Endocrinol Metab 88: 4100-4104, 2003.
16. 18F-fluorodeoxyglucose uptake in thyroid from positron emission tomogram (PET) for evaluation in cancer patients: high prevalence of malignancy in thyroid PET incidentaloma. Laryngoscope 115: 1074-1078, 2005.
17. Bloom AD, Adler LP and Shuck JM: Determination of malignancy of thyroid nodules with positron emission tomography. Surgery 114: 728-734, 1993.
18. Uematsu H, Sadato N, Ohtsubo T, Tsuchida T, Nakamura S, Sugimoto K, Waki A, Takahashi N, Yonekura Y, Tsuda G, Saito H, Hayashi N, Yamamoto K and Ishii Y: Fluorine-18-fluorodeoxyglucose PET versus thallium-201 scintigraphy evaluation of thyroid tumors. J Nucl Med 39: 453-459, 1998.
19. Kresnik E, Gallowitsch HJ, Mikosch P, Stettner H, Igerc I, Gomez I, Kumnig G and Lind P: Fluorine-18-fluorodeoxyglucose positron emission tomography in the preoperative assessment of thyroid nodules in an endemic goiter area. Surgery 133: 294-299, 2003.
20. 18F-FDG PET/CT: clinical significance and improved characterization. J Nucl Med 47: 609-615, 2006.
21. 18FDG-PET/ CT. Surgery 138: 1166-1174, 2005.
22. Higashi K, Matsunari I, Ueda Y, Ikeda R, Guo J and Oguchi M: Value of whole-body FDG PET in management of lung cancer. Ann Nucl Med 17: 1-14, 2003.
23. Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Thomas J and de Groot T: Early restaging positron emission tomography with (18)Ffluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 13: 1356-1363, 2002.
24. Benard F, Romsa J and Hustinx R: Imaging gliomas with positron emission tomography and single-photon emission computed tomography. Semin Nucl Med 33: 148-162, 2003.
25. 18F-FDG PET for the diagnosis and grading of soft-tissue sarcoma: a meta-analysis. J Nucl Med 44: 717-724, 2003.
26. Joensuu H and Ahonen A: Imaging of metastasis of thyroid carcinoma with fluorine-18-fluorodeoxyglucose. J Nucl Med 28: 910-914, 1987.
27. Feine U, Lietzenmayer R, Hanke JP, Held J, Wohrle H and Muller-Schauenburg W: Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 37: 1468-1472, 1996.
28. 18F]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. Thyroid 11: 1169-1175, 2001.
29. Grunwald F, Kalicke T, Feine U, Lietzenmayer R, Scheidhauer K and Dietlein M: Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 26: 1547-1552, 1999.
30. Helal BO, Merlet P, Toubert ME, Franc B, Schvartz C and Gauthier-Koelesnikov H: Clinical impact of (18)F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy. J Nucl Med 42: 1464-1469, 2061.
31. 131I whole-body scan. J Nucl Med 40: 993-994, 1999.
32. Dietlein M, Scheidhauer K, Voth E, Theissen P and Schicha H: Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 wholebody scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 24: 1342-1348, 1997.
33. Wong CO and Dworkin HJ: Role of FDG PET in metastatic thyroid cancer. J Nucl Med 40: 993-994, 1999.
34. 131I in patients with metastatic thyroid carcinoma. Nucl Med Commun 18: 3-9, 1997.
35. Conti PS, Durski JM, Bacqai F, Grafton ST and Singer PA: Imaging of locally recurrent and metastatic thyroid cancer with positron emission tomography. Thyroid 9: 797-804, 1999.
36. 18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab 85: 1107-1113, 2000.
37. 131I scan. J Nucl Med 42: 77-78, 2001.
38. Shiga T, Tsukamoto E, Nakada K, Morita K, Kato T and Mabuchi M: Comparison of (18)F-FDG, (131)I-Na, and (201)TI in diagnosis of recurrent or metastatic thyroid carcinoma. J Nucl Med 42: 414-419, 2001.
39. 18F-FDG PET. Eur J Nucl Med Mol Imaging 29: 231-236, 2002.
40. Grant S, Luttrell B, Reeve T, Wiseman J, Wilmshurst E and Stiel J: Thyroglobulin may be undetectable in the serum of patients with metastatic disease secondary to differentiated thyroid carcinoma. Follow-up of differentiated thyroid carcinoma. Cancer 54: 1625-1628, 1984.
41. Preissner CM, O'Kane DJ, Singh RI, Morris JC and Grebe SK: Phantoms in the assay tube: heterophile antibody interferences in serum thyroglobulin assays. J Clin Endocrinol Metab 88: 3069-3074, 2003.
42. Muller-Gartner HW and Schneider C: Clinical evaluation of tumor characteristics predisposing serum thyroglobulin to be undetectable in patients with differentiated thyroid cancer. Cancer 61: 976-981, 1988.
43. Hung MC, Wu HS, Kao CH, Chen WK and Changlai SP: F18-fluorodeoxyglucose positron emission tomography in detecting metastatic papillary thyroid carcinoma with elevated human serum thyroglobulin levels but negative I-131 whole body scan. Endocrinol Res 29: 169-175, 2003.
44. Sisson JC, Ackermann RJ, Meyer MA and Wahl RL: Uptake of 18-fluoro-2-deoxy-D-glucose by thyroid cancer: implications for diagnosis and therapy. J Clin Endocrinol Metab 77: 1090-1094, 1993.
45. van Tol KM, Jager PL, Piers DA, Pruim J, de Vries EG and Dullaart RP: Better yield of (18)fluorodeoxyglucose-positron emission tomography in patients with metastatic differentiated thyroid carcinoma during thyrotropin stimulation. Thyroid 12: 381-387, 2002.
46. 18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 84: 2291-2302, 1999.
47. Moog F, Linke R, Manthey N, Tiling R, Knesewitsch P and Tatsch K: Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma. J Nucl Med 41: 1996-1998, 2000.
48. Petrich T, Borner AR, Otto D, Hofmann M and Knapp WH: Influence of rhTSH on [(18)F]fluorodeoxyglucose uptake by differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging 29: 641-647, 2002.